Pamulapati, Chandrasena
Boehringer Ingelheim (United States)
2 papers on CoChat
Most cited papers
- Verified
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Feagan, B. G., Sandborn, W. J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. (2017) · The Lancet
Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis
Cited by 451
- Verified
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Baeten, D., Østergaard, M., Wei, J. C.-C., Sieper, J., Järvinen, P., Tam, L.-S., Salvarani, C., Kim, T.-H., Solinger, A., Datsenko, Y., et al. (2018) · Annals of the Rheumatic Diseases
Spondyloarthritis Studies and TreatmentsPsoriasis: Treatment and Pathogenesis
Cited by 390
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free